In today’s Pharmaceutical Executive Daily, we cover the resignation of Organon CEO Kevin Ali following an internal investigation tied to Nexplanon sales, GSK’s $357 million agreement with Syndivia to expand its antibody-drug conjugate portfolio, and new guidance from the American College of Surgeons classifying obesity as a treatable condition.

Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns

<div>The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and <a href="http://PharmExec.com">PharmExec.com</a> to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. </div>

Science

Life Sciences

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and <a href="http://PharmExec.com" rel="noopener noreferrer">PharmExec.com</a> to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.&nbsp;

Share Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns

Sign up to save your podcasts

Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns

Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns

More shows like Pharmaceutical Executive

Global News Podcast

WSJ Your Money Briefing

WSJ What’s News

The McKinsey Podcast

WSJ Tech News Briefing

HBR IdeaCast

WSJ Minute Briefing

Bold Names

The Readout Loud

Thoughts on the Market

The Journal.

BioCentury This Week

Biotech Hangout

The So What from BCG

WSJ's Take On the Week